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Self-induction of rifampicin metabolism during daily and intermittent
chemotherapy was studied by monitoring the changes in the serum half-life
of the drug over a 4-week period in patients with pulmonary tuberculosis.
Rifampicin 450 mg was administered to 8 patients who received treatment
daily, 7 on thrice-weekly and 7 others on twice-weekly treatment. Serum
half-life was computed from concentrations of the drug determined at 3, 4½
and 6 hours after drug administration, on admission and at 1, 2 and 4 weeks
after start of treatment. In the daily series, the mean serum half-life
decreased from 4.9 hours on admission to 3.6 hours at 1 week (P = 0.02),
and treatment beyond this had no further effect. In the thrice-weekly series,
maximal induction was observed at the 2nd week, the mean values on
admission and at 2 weeks being 5.8 and 3.7 hours, respectively (P < 0.01). In
the twiceweekly series, maximal induction was observed only at the 4th
week, the mean values on admission and at 4 weeks being 4.9 and 3.7 hours,
respectively (P < 0.01).
Serum activity of gamma glutamyl transferase was not found to be a suitable
in vivo marker to monitor induction of the hepatic microsomal enzymes as
no significant changes were observed in the activity of this enzyme in any of
the 3 series during the 4-week period.
Treatment of tuberculosis with fully intermittent short-course regimens containing
rifampicin in addition to isoniazid, pyrazinamide and streptomycin has been shown to be as
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Table 1. Dosages of drugs
Regimens
Rifampicin (mg) 450 450 450
Isoniazid (mg) 300 450 600
Ethambutol (mg) 800 1200 1600
Pyrazinamide (g) 1.5 1.5 2.0
6 hours according to the method of Dickinson et al7 employing a strain of Staphylococcus
Aureus (Sub group I, NCTC 10702) resistant to streptomycin and other antibiotics.
Rifampicin standards ranging from 0.04 to 1.28 µg/ml were set up in quadruplicate and the
concentrations of the drug in the samples (set up in quadruplicate in dilutions of 1 in 5 and
1 in 10) were obtained from the regression line of the log concentration of the standard on
the diameter of the zone of inhibition. Serum activity of GGT was determined in the
samples collected at 0 hour employing a standard procedure8. All determinations were
undertaken after randomizing the samples.
Assuming first order kinetics, the disposition rate constant (K) was calculated from the
regression of log rifampicin concentrations in serum on time, and the half-life (t½) was
obtained from the equation t ½ = 0.693/K.
Student’s t-test (paired) was employed for testing the differences between the mean
values at the different weeks in each group.
 A total of 36 patients (12 each in R7, R3 and R2 ) were selected for the study. Of them, 3
patients (2 R7 and 1 R3) were excluded from analysis due to inadequate chemotherapy
(missed more than 10% of their scheduled chemotherapy) or had missed their doses on the
occasion prior to the test-day on any of the 4 occasions, and 2 patients (1 R3 and 1 R2) were
withdrawn from the study on clinical grounds. Further, serum half-life of rifampicin could
not be calculated in 9 patients and-were excluded; in 7 of these (3 R3 and 4 R2), the peak
concentrations were attained at the 6th hour, while there was practically no change in the
concentrations at. the 3 time-points in the remaining 2 patients (both R7). The analysis is,
therefore, based on 22 patients (8 R7, 7 R3 and 7 R2). The GGT values and certain pre-
treatment disease characteristics such as the radiographic extent of lung lesions and results
of sputum smear examination were similar in the exclusions and those retained in the
analysis. The mean body-weight of the 22 patients in the analysis was 42 kg (range : 32- 54
kg), and the mean dosages of rifampicin administered were 10.7, 10.7, and 11.3 mg/kg in
R7, R3 and R2 series, respectively.
The mean serum rifampicin concentrations at 3, 4½ and 6 hours on admission (0 week)
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Fig.1. Mean serum rifampicin concentrations at 3, 4½ and 6 hours on admission ( l      l ),
and 1 week ( ¡       ¡  ), 2 weeks ( n n ), and 4 weeks ( o    o ) of
treatment with daily, thrice-weekly and twice-weekly regimens containing rifampicin
and at 1, 2 and 4 weeks after start of treatment in the 3 groups are presented in figure 1; the
mean serum half-lives are presented in table 2.
Table 2. Serum half-life of rifampicin during treatment with daily, thrice-weekly and mice-weekly
regimens containing the drug
Week
Serum half-life of rifampicin (hours)
R7 R3 R2
0
No. of patients 8 7 7
*Geometric mean with the range in parenthesis.
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Serum concentrations of rifampicin were highest on admission in all the 3 groups of
patients and there was an exponential fall between the 3rd and the 6th hour on all the test
days. In the daily series, the mean serum half life of rifampicin at 1 week was significantly
lower than that on admission (P = 0.02); subsequent treatment had no effect and the
means at 1, 2 and 4 weeks were similar (P > 0.2). In the thrice-weekly series, the decrease
at 1 week was not significant (P > 0.1); however, the mean value at 2 weeks was
significantly lower than that on admission (P < 0.01). Further, thrice-weekly treatment had
no effect and the difference in the mean values between the 2nd and the 4th weeks was not
significant (P > 0.2). In the twice-weekly series, the values at 0, 1 and 2 weeks were similar;
the mean value at the 4th week was, however, appreciably lower than those during the
preceding weeks (P < 0.01).
The mean GGT values (not tabulated) on admission and at the end of 4 weeks of
treatment were 33 and 38 IU/L in the R, series, 38 and 25 IU/L in the R3 series and 37 and
25 IU/L in the R2 series. The slight increase observed in the daily series and the decreases
in the thrice-weekly and the twice-weekly series were not significant (P > 0.1 for all).
Discussion
The primary step in the metabolism of rifampicin is hydrolysis to desacetylrifampicin.
Serum concentrations of rifampicin were determined by the plate diffusion assay
employing Staph. aureus7. It has been demonstrated that the activity of desacetylrifampicin
against this organism is only about 20-25% of that of rifampicin7, and that the metabolite
forms only a small proportion (< 15%) of the total circulating rifampicin in human
subjects’. Thus, the changes observed in serum concentrations would almostentirely reflect
those of unchanged rifampicin.
Investigations undertaken earlier at this Centre in healthy subjects had shown that the
mean serum half-life of rifampicin was 4.9 hours at the start of rifampicin administration
and that maximal induction of the metabolism of the drug, and presumably that of the
hepatic microsomal enzyme system in general, was attained after 7 daily doses of the drug5.
Similar findings have been reported by Acocella et al4. Results reported in this
communication show that the maximal induction of rifampicin metabolism was observed
after 1 week of treatment (7 doses) in the R7 series, at 2 weeks (6 doses) in the R3 series
and at 4 weeks (8 doses) in the R2 series. These findings suggest that maximal induction of
the metabolism of this drug is attained with about 6-8 doses of the drug irrespective of the
frequency of administration. However, the incidence of hepatitis, attributed to the release
of hydrazine following induction of isoniazid hydrolase3, was substantially higher during
daily treatment with a combination of rifampicin and isoniazid than during thrice-weekly or
twice-weekly treatment with regimens containing the same drugs2, and hepatitis tended to
occur early on during treatment2,10. It is, therefore, possible that occurrence of hepatitis is
also related to the speed with which maximal induction of isoniazid hydrolase is attained.
The dosages of isoniazid, pyrazinamide and ethambutol administered to the 3 groups of
patients were different for reasons of therapeutic efficacy and toxicity. It has been shown
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that isoniazid does not affect the bio-disposition of rifampicin11,12 and to the best of our
knowledge, the effect of pyrazinamide and ethambutol have not been studied so far. It is
unlikely that these two compounds will have any effect as they are not known to induce the
hepatic microsomal enzyme system, and the pathways of metabolism and excretion are
different. Further, all patients admitted to the study (by random allocation) were from the
poorest socio-economic strata of the population of Madras City and as such, dietary factors
and nutritional status, which could influence the biodisposition of drugs, would not be
radically different in the 3 groups. In any case, the effect of the dosages of the companion
drugs and dietary factors would be much less than the effect of the induction by rifampicin
of the hepatic microsomal enzyme system on the metabolism of the drug.
The changes observed in the serum activities of GGT before and at the end of 4 weeks
of treatment were not significant in any of the 3 series. Ohnhaus et al13 also did not observe
any significant increase in the GGT activity following 8 daily doses of 1200 mg (2 x 600
mg) of rifampicin, while there was a 7-fold increase in the excretion of 6- b -hydroxycortisol
during the same period. It is thus obvious that GGT activity cannot be used to monitor
enzyme induction in the hepatocyte during rifampicin treatment and that more sensitive
markers such as the urinary excretion of 6- b -hydroqcortisol should be employed for this
purpose.
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